D10 Infusion for Hypoglycemia

Initial Treatment Protocol

The American College of Cardiology recommends administering 5-10 gram aliquots (50-100 mL) of D10 intravenously every 1-2 minutes until symptoms resolve, with a target post-treatment glucose of 100-180 mg/dL 1
Titrated dosing is superior to bolus administration, correcting blood glucose into the target range in 98% of patients within 30 minutes while avoiding dangerous overcorrection 1
A patient-specific formula can guide dosing: (100 − current blood glucose in mg/dL) × 0.2 grams = total dose of dextrose needed 1
For continuous infusion in insulin overdose or prolonged hypoglycemia, start D10 at 100 mL/kg per 24 hours (approximately 4.2 mL/kg/hour or 7 mg/kg/minute) 2
Titrate the infusion rate to maintain blood glucose between 100-180 mg/dL 2

Recheck blood glucose 15 minutes after initial treatment, as additional doses are frequently needed 1
Repeat glucose measurement at 60 minutes, as the effect may be temporary 1
Monitor blood glucose every 1-2 hours during any ongoing dextrose infusion 1, 2
Check serum potassium and sodium levels carefully, as dextrose administration can cause electrolyte shifts 2
Monitor every 30-60 minutes initially when starting continuous infusion 2

Avoid reflexive full-dose administration, as it can cause excessive blood glucose elevation and has been associated with cardiac arrest and hyperkalemia when given rapidly and repeatedly 1
Titrate based on initial glucose level and patient response rather than administering fixed large doses 1
Never abruptly discontinue dextrose infusion in insulin overdose patients 2
Reduce infusion rate by 50% over the final 30 minutes before discontinuing to prevent rebound 2

Children require 15-20 grams of glucose for moderate hypoglycemia 1
For pediatric patients, D5W should be administered as a constant infusion at 100 mL/kg per 24 hours (approximately 7 mg/kg/min) with appropriate maintenance electrolytes 3
IV dextrose is preferred over glucagon due to faster response time 1
For conscious patients able to swallow, oral glucose is first-line treatment, according to the American Heart Association, as published in Circulation 4